Keyword: Bristol-Myers Squibb
After posting sinking response rates, Nektar unveiled new results for its NKTR-214 and Opdivo melanoma therapy that showed rates holding just steady.
SITC kicked off with a stack of new data on immuno-oncology drugs, including a first look at Merck’s early-stage drugs targeting LAG-3 and TIGIT.
Roche is licensing Halozyme's Enhanze drug delivery platform for three new targets. Halozyme could receive up to $165 million in milestones per target.
We caught up with Tony Johnson, CEO at Goldfinch Bio, and discussed why investment and development in kidney disease has lagged.
The Big Pharma is investing $12 million in Compugen as part of a deal that gives it the right to first negotiations for the COM701 license.
BMS’ tyrosine kinase 2 inhibitor checked off a phase 2 psoriasis trial, showing high levels of skin clearance after three months of daily treatment.
An Allergan architect bids farewell as its board revamp continues; Gilead steals the commercial chief from Amgen; Editas loses its CMO and more.
After raising more than $194 million in venture capital, Gritstone is looking to raise up to $80 million in its IPO.
Harbour BioMed licensed a midphase PD-L1 antibody from Kelun Biotech for development and commercialization outside of Greater China.